How much funding has MBX Biosciences raised?

MBX Biosciences has raised $113.1M in total funding, most recently a Series C round.

Who are MBX Biosciences's investors?

MBX Biosciences's investors include Frazier Healthcare, J.P. Morgan, Deep Track Capital, New Enterprise Associates, OrbiMed, Jefferies.

When was MBX Biosciences founded?

MBX Biosciences was founded in 2018.

Where is MBX Biosciences headquartered?

MBX Biosciences is headquartered in Carmel.

What industry is MBX Biosciences in?

MBX Biosciences operates in Healthcare.

How many employees does MBX Biosciences have?

MBX Biosciences has 11-50 employees.

MBX Biosciences

IPO

Precision Therapeutics. Simplified Disease Management.

Public · Carmel · Founded 2018 · $113.1M raised

Healthcare

Headquarters: Carmel
Employees: 11–50
Founded: 2018
Business Model: B2B
Website: mbxbio.com

Total Funding: $113.1M
Last Round: $63.5M Series CAug 2024
Rounds: 3
Type: Public

About

MBX Biosciences is pioneering Precision Endocrine Peptide (PEP) therapeutics for patients with endocrine and metabolic disorders. Its pipeline includes MBX 2109 (Phase 2, hypoparathyroidism), MBX 1416 (Phase 1, post-bariatric hypoglycemia), and pre-clinical obesity programs. The company went public on Nasdaq (MBX) in September 2024.

Summary

MBX Biosciences is a Healthcare company based in Carmel, founded in 2018. It has raised $113.1M in total across 3 rounds, most recently a $63.5M Series C round in Aug 2024. Investors include Frazier Healthcare, J.P. Morgan and Deep Track Capital.

LinkedIn X (Twitter)